FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201417032> ?p ?o ?g. }

• W3201417032 endingPage "100269" @default.
• W3201417032 startingPage "100269" @default.
• W3201417032 abstract "A favorable model for predicting disease-free survival (DFS) and stratifying prognostic risk in breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) is lacking. The aim of the current study was to formulate an excellent model specially for predicting prognosis in these patients.Between January 2012 and December 2015, 749 early-stage BC patients who received NAC in Xijing hospital were included. Patients were randomly assigned to a training cohort (n = 563) and an independent cohort (n = 186). A prognostic model was created and subsequently validated. Predictive performance and discrimination were further measured and compared with other models.Clinical American Joint Committee on Cancer stage, grade, estrogen receptor expression, human epidermal growth factor receptor 2 (HER2) status and treatment, Ki-67 expression, lymphovascular invasion, and residual cancer burden were identified as independent prognostic variables for BC treated with NAC. The C-index of the model consistently outperformed other available models as well as single independent factors with 0.78, 0.80, 0.75, 0.82, and 0.77 in the training cohort, independent cohort, luminal BC, HER2-positive BC, and triple-negative BC, respectively. With the optimal cut-off values (280 and 360) selected by X-tile, patients were categorized as low-risk (total points ≤280), moderate-risk (280 < total points ≤ 360), and high-risk (total points >360) groups presenting significantly different 5-year DFS of 89.9%, 56.9%, and 27.7%, respectively.In patients with BC, the first model including residual cancer burden index was demonstrated to predict the survival of individuals with favorable performance and discrimination. Furthermore, the risk stratification generated by it could determine the risk level of recurrence in whole early-stage BC cohort and subtype-specific cohorts, help tailor personalized intensive treatment, and select comparable study cohort in clinical trials." @default.
• W3201417032 created "2021-09-27" @default.
• W3201417032 creator A5002099920 @default.
• W3201417032 creator A5003716350 @default.
• W3201417032 creator A5004886391 @default.
• W3201417032 creator A5018161360 @default.
• W3201417032 creator A5032436944 @default.
• W3201417032 creator A5032731708 @default.
• W3201417032 creator A5039704967 @default.
• W3201417032 creator A5042648241 @default.
• W3201417032 creator A5049386904 @default.
• W3201417032 creator A5050351141 @default.
• W3201417032 creator A5052936351 @default.
• W3201417032 creator A5065709688 @default.
• W3201417032 creator A5065897640 @default.
• W3201417032 creator A5073078773 @default.
• W3201417032 creator A5079461776 @default.
• W3201417032 creator A5082456616 @default.
• W3201417032 creator A5085402542 @default.
• W3201417032 creator A5086473875 @default.
• W3201417032 creator A5090750513 @default.
• W3201417032 creator A5091432278 @default.
• W3201417032 date "2021-10-01" @default.
• W3201417032 modified "2023-10-15" @default.
• W3201417032 title "Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy" @default.
• W3201417032 cites W1555003755 @default.
• W3201417032 cites W1891489226 @default.
• W3201417032 cites W1964002628 @default.
• W3201417032 cites W2025644992 @default.
• W3201417032 cites W2045030989 @default.
• W3201417032 cites W2075894019 @default.
• W3201417032 cites W2084426972 @default.
• W3201417032 cites W2096145980 @default.
• W3201417032 cites W2105219549 @default.
• W3201417032 cites W2108410268 @default.
• W3201417032 cites W2109462843 @default.
• W3201417032 cites W2112358255 @default.
• W3201417032 cites W2112907781 @default.
• W3201417032 cites W2114586150 @default.
• W3201417032 cites W2116522870 @default.
• W3201417032 cites W2129925362 @default.
• W3201417032 cites W2133650808 @default.
• W3201417032 cites W2146165949 @default.
• W3201417032 cites W2146999964 @default.
• W3201417032 cites W2151552922 @default.
• W3201417032 cites W2151570079 @default.
• W3201417032 cites W2170003495 @default.
• W3201417032 cites W2283816551 @default.
• W3201417032 cites W2301046115 @default.
• W3201417032 cites W2521999419 @default.
• W3201417032 cites W2530275674 @default.
• W3201417032 cites W2585697071 @default.
• W3201417032 cites W2611609325 @default.
• W3201417032 cites W2620769019 @default.
• W3201417032 cites W2771978163 @default.
• W3201417032 cites W2788567355 @default.
• W3201417032 cites W2802517176 @default.
• W3201417032 cites W2907566829 @default.
• W3201417032 cites W2909659250 @default.
• W3201417032 cites W2913236879 @default.
• W3201417032 cites W2944108263 @default.
• W3201417032 cites W2979291688 @default.
• W3201417032 cites W3011559189 @default.
• W3201417032 cites W3015004022 @default.
• W3201417032 cites W3039622435 @default.
• W3201417032 cites W3041063457 @default.
• W3201417032 cites W3044442852 @default.
• W3201417032 cites W3082472009 @default.
• W3201417032 cites W3126786489 @default.
• W3201417032 cites W3159796473 @default.
• W3201417032 cites W4248525000 @default.
• W3201417032 doi "https://doi.org/10.1016/j.esmoop.2021.100269" @default.
• W3201417032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8455687" @default.
• W3201417032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34537675" @default.
• W3201417032 hasPublicationYear "2021" @default.
• W3201417032 type Work @default.
• W3201417032 sameAs 3201417032 @default.
• W3201417032 citedByCount "4" @default.
• W3201417032 countsByYear W32014170322022 @default.
• W3201417032 countsByYear W32014170322023 @default.
• W3201417032 crossrefType "journal-article" @default.
• W3201417032 hasAuthorship W3201417032A5002099920 @default.
• W3201417032 hasAuthorship W3201417032A5003716350 @default.
• W3201417032 hasAuthorship W3201417032A5004886391 @default.
• W3201417032 hasAuthorship W3201417032A5018161360 @default.
• W3201417032 hasAuthorship W3201417032A5032436944 @default.
• W3201417032 hasAuthorship W3201417032A5032731708 @default.
• W3201417032 hasAuthorship W3201417032A5039704967 @default.
• W3201417032 hasAuthorship W3201417032A5042648241 @default.
• W3201417032 hasAuthorship W3201417032A5049386904 @default.
• W3201417032 hasAuthorship W3201417032A5050351141 @default.
• W3201417032 hasAuthorship W3201417032A5052936351 @default.
• W3201417032 hasAuthorship W3201417032A5065709688 @default.
• W3201417032 hasAuthorship W3201417032A5065897640 @default.
• W3201417032 hasAuthorship W3201417032A5073078773 @default.
• W3201417032 hasAuthorship W3201417032A5079461776 @default.
• W3201417032 hasAuthorship W3201417032A5082456616 @default.
• W3201417032 hasAuthorship W3201417032A5085402542 @default.

• next